All News

COVID-19 vaccination before infection significantly reduces hospitalization, critical care admissions, and preterm birth rates in pregnant individuals, study finds.

Your daily dose of the clinical news you may have missed.

FDA prioritizes review of Tzield for young children with stage 2 type 1 diabetes, potentially delaying disease onset and improving patient outcomes.

Your daily dose of the clinical news you may have missed.

The FDA has accepted a supplemental NDA for AXS-05 for agitation associated with Alzheimer disease and granted Priority Review, with a PDUFA action date of April 30, 2026.

Take a quick look back at developments this year with our higlights of acceleration of DMTs, particularly focusing on anti-amyloid antibodies and novel oral agents.

Clevenger explains how better recognition of agitation in Alzheimer disease, and stronger caregiver–clinician communication, can meaningfully improve outcomes.

A multidisciplinary panel of neurologists, geriatricians, and researchers examined how early identification, equitable access, and value-based models could reshape Alzheimer disease care.

Stay informed with the latest critical updates, including new guidelines, vaccine insights, and groundbreaking research findings from 2025.

Abbott's Volt PFA System gains FDA approval, offering a new minimally invasive treatment for atrial fibrillation, enhancing patient care options.

Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.

Completion of the screening pathway—not test selection alone—may define quality going forward.

Real-world patient cases illustrating how pill burden, privacy, and individual preferences influence PrEP selection and adherence.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Phase 3 LIBerate data showed sustained LDL-C reductions of 60% or more in high-risk patients and 50% or more in HeFH, with once-monthly self-administration.

Primary care physician Kevin Hatfield, MD, discusses how the switch can increase patient touchpoints, free cognitive burden, and strengthen long-term engagement between patients and PCPs.